http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9fe5ea6c8b32fff4b1b72a0860add5cc
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Liotta |
| name | Lance A. Liotta Lance A Liotta |
| given-name | Lance A. Lance A |
| organization-name | Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, Istituto Dermopatico dell’Immacolata, 00167 Rome, Italy, and Department of Urology, University of California-Irvine, Orange, California 92868 National Institute of Health, National Cancer Institute Bethesda Maryland Center for Applied Proteomics and Molecular Medicine, College of Science, George Mason University, Fairfax, Virginia Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, Department of Physics, The George Washington University, Washington, D.C., 20052, Plant-Microbe Genomics Facility, The Ohio State University, Columbus, Ohio 43210, eehscience LLC, Pickerington, Ohio 43147, Department of Electrical and Computer Engineering, Wayne State University, Detroit, Michigan 48202, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University College of Medicine, Columbus,... Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, Center for Experimental Research and Medical Studies, San Giovanni Battista Hospital, Turin 10126, Italy, Department of Medicine and Experimental Oncology, University of Turin, Turin 10125, Italy, and Diabetes Research Institute, San Raffaele Scientific Institute, Milano 20132, Italy Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, Laboratory of Pathology, National Cancer Institute, and Mathematical and Statistical Computing Laboratory, Center for Information Technology, National Institutes of Health, Bethesda, MD 20892; Department of Health Evaluation Sciences, P.O. Box 800717, University of Virginia School of Medicine, Charlottesville, VA 22908; and Tissue Proteomics Unit, Division of Therapeutic Proteins, Center for Biologics Evaluation and Research,... National Cancer Institute/NIH Bethesda Maryland Authors' Affiliations: 1Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia; 2Institute of Pathology and 3Institute of Obstetrics and Gynecology, Technische Universität München, Munich, Germany; 4University of California at San Francisco, San Francisco, California; 5Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; 6Institute of Pathology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany; 7Institute of Pathology and 8Institute of Gynecology, Rosenheim Clinic, Rosenheim, Germany Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA Office of the Chief, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Authors' Affiliation: Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, College of Science, George Mason University, Manassas, Virginia 1Laboratory of Pathology, Center for Cancer Research, National Cancer Institute,; 2FDA-NCI Clinical Proteomics Program and Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA. [email protected] Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany, Department of Surgery, University of California San Francisco Medical School, San Francisco, California 94115, Department of Oncological and Surgical Sciences, Unversity of... M. R. Emmert-Buck, R. F. Chuaqui, Z. Zhuang, R. A. Weiss, L. A. Liotta, Laboratory of Pathology, National Cancer Institute, Room 2A33, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA. Authors' Affiliations: 1Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità; 2Regina Elena National Cancer Institute, Rome, Italy; 3Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas; and 4Department of Computer Science, School of Engineering, Virginia Commonwealth University, Richmond, Virginia National Institutes of Health Center for Applied Proteomics and Molecular Medicine George Mason University Manassas VA USA 3National Cancer Institute Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and Office of the Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD 20892 Center For Applied Proteomics and Molecular Medicine (CAPMM) School of Systems Biology, College of Sciences, George Mason University, Manassas, VA 20110, USA Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA. Center for Applied Proteomics and Molecular Medicine; George Mason University; Manassas VA USA Department of Clinical and Experimental Medicine, Magna Græcia University, 88100 Catanzaro, Italy, Division of Hematology and Oncology, Internal Medicine, The Ohio State University, Columbus Ohio 43210, TASC-INFM CNR, S.S. 14 Km163.5, Area Science Park, I-34012 Basovizza, Trieste, Italy, and Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas Virginia 20110 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA S. C. Chandrasekharappa, S. C. Guru, P. Manickam, S.-E. Olufemi, F. S. Collins, Laboratory of Gene Transfer, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.; M. R. Emmert-Buck, L. V. Debelenko, Z. Zhuang, I. A. Lubensky, L. A. Liotta, Laboratory of Pathology, National Cancer Institute (NCI), NIH, Bethesda, MD 20892, USA.; J. S. Crabtree, Y. Wang, B. A. Roe, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA.; J. Weisemann and M. S. Boguski, National Center for Biotechnology Information, National Library of Medicine (NLM), NIH, Bethesda, MD 20894, USA.; S. K. Agarwal, M. B. Kester, Y. S. Kim, C. Heppner, Q. Dong, A. M. Spiegel, A. L. Burns, S. J. Marx, Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD 20892, USA. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA Authors' Affiliations: 1Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy; and 2Center for Applied Proteomics and Molecular Medicine and 3School of Systems Biology, George Mason University, Manassas, Virginia Laboratory of Pathology, Division of Cancer Biology, Diagnosis and Centers, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 National Cancer Institute, NIH Bethesda Maryland FDA-NCI Clinical Proteomics Program, Office of the Director, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, 20892, Bethesda, Maryland Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, Virginia, USA the Laboratory of Pathology, National Cancer Institute (L.V.D., M.R.E., Z.Z., I.A.L., L.A.L.); Bethesda, Maryland 20892 1Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland; Authors' Affiliations: 1Duke University Medical Center, Durham, North Carolina; 2George Mason University, Center for Applied Proteomics and Molecular Medicine, Manassas, Virginia; 3Texas A&M Health Sciences Center, College of Medicine, Round Rock; and 4MD Anderson Cancer Center, Houston, Texas *Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110 FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Office of Cellular and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, and Department of Pathology, Division of Translational Pathology, University of Texas Southwestern, Dallas, Texas 75390 2National Cancer Institute-Food and Drug Administration Clinical Proteomics Group, Laboratory of Pathology, and †Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and The Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, United States Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, United States Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia Laboratory of Pathophysiology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA 1National Cancer Institute-Food and Drug Administration Clinical Proteomics Program, Laboratory of Pathology, and NCI/FDA Clinical Proteomics Program, Office of the Director, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892; NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 CRO-IRCCS National Cancer Institute, Aviano, Italy, Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, and Department of Chemistry and Biochemistry, George Mason University, Manassas, Virginia 20110 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute/NIH, Bethesda, MD, USA. 3Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; 7Laboratory of Pathology; and George Mason University, Center for Applied Proteomics & Molecular Medicine, 10900 University Boulevard, MS1A9, Manassas, VA 20110, USA Laboratory of Pathology, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland 20892 Center for Applied Proteomics and Molecular Medicine, Institute for Advanced Biomedical Research College of Science, George Mason University, Manassas, Virginia 1George Mason University, Manassas, Virginia. Center for Applied Proteomics and Molecular Medicine, College of Science, George Mason University, Manassas, Virginia Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland, Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia, Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, Department of Urology, University at Buffalo, State University of New York, Buffalo, New York, Department of Surgery (Division of Urology) and University of North Carolina Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel... Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 2Laboratory of Pathology, George Mason University, Manassas, VA, 20110, USA. [email protected]. Center for Applied Proteomics and Molecular Medicine, George Mason University, 10920 George Mason Circle, Manassas, VA, 20110, USA. [email protected]. Center for Applied Proteomics and Molecular Medicine George Mason University Manassas Virginia USA Deputy Director for Intramural Research, National Institutes of Health, Bethesda, MD 20892 NCI/FDA Clinical Proteomics Program, Office of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, and NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 Center for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Boulevard, Manassas, VA 20110, USA. George Mason University, Manassas, Virginia. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, and Department of Pathology, Suburban Hospital, Bethesda, Maryland 20814 3Clinical Proteomics Program, Food and Drug Administration-National Cancer Institute, Bethesda, Maryland; and NCI-FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA NCI-FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 Center for Applied Proteomics and Molecular Medicine, George Mason University , Manassas, VA, USA From the US Food and Drug Administration (FDA) –National Cancer Institute (NCI) Clinical Proteomics Program, Office of Cellular and Gene Therapy, Center for Biologics Evaluation and Research (CBER), FDA; FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, NCI, Center for Cancer Research (CCR)/National Institutes of Health (NIH); Biostatistics Section, Mathematical and Statistical Computing Laboratory, Center for Information Technology, NIH, Bethesda; Johns Hopkins University, Department of... Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA From the Center for Research on Reproduction and Women's Health, Abramson Family Cancer Research Institute, Department of Medicine Division of Hematology-Oncology, and Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA; University of Michigan, Ann Arbor, MI; Center for Applied Proteomics and Molecular Medicine, George Mason University, Fairfax, VA; Department of Obstetrics and Gynecology, University of Turin, Turin, Italy; and Molecular Biology and Genetics Program... Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA. [email protected]. 1Laboratory of Pathology, National Cancer Institute, Center for Cancer Research;; 3Food and Drug Administration–National Cancer Institute Clinical Proteomics Program, Bethesda, Maryland FDA-NCI Clinical Proteomics Program Laboratory of Pathology National Cancer Institute National Institutes of Health Bethesda, MD 20892, USA Laboratory of PathologyNational Cancer Institute, DCBDCNational Institutes of HealthBethesdaMaryland20892USA George Mason University Manassas VA USA Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20205 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 M. Emmert-Buck, K. Cole, R. Chuaqui, and L. Liotta are in the Laboratory of Pathology, National Cancer Institute, Frederick, MD. Authors' Affiliations: 1Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia; 2Departments of Neurosurgery, Henry Ford Hospital, Detroit; and 3Pathology, Henry Ford Hospital, Detroit, Michigan ms George Mason University , Manassas , VA , USA. Center for Applied Proteomics and Molecular Medicine, College of Arts and Sciences, George Mason University, Manassas, Virginia 20110, USA. [email protected] |
Incoming Links
Showing number of triples: 1 to 522 of 522.